About Us

MaxiNovel Pharmaceuticals Co.,Ltd. is a China based biotech company founded in 2016 to focus on the innovative drug research with the global intellectual property rights.

We carry out first-in-class small molecule drug discovery in the areas of targeted therapy and immunotherapy. Our rapidly expanding product pipeline is mainly composed of programs that target both blood tumors and solid tumors as well as autoimmune diseases. Company’s research platforms encompass oral therapy, radiotherapy, imaging and transdermal therapy.

We have our R&D and operation centers in China (Shanghai, Guangzhou, Shenzhen), the United States and Australia.  Our management team members all have extensive previous working experiences in global pharmaceutical companies and capital markets, more importantly global vision of our company’s future development.

Our mission is to conduct pharmaceutical innovation to save lives and bring hopes to patients and their families.

Guangzhou Biomarker and Translational
Research Center
ShanghaiR&D and Operation Management Center
SydneyClinical Operation Management Office
New JerseyInternational Registration
& Clinical Operation
Management Office

Transdermal Drug
Delivery R&D Center

Biomarkers and Translational Medicine
Drug Development Center
Clinical center
New Jersey
Registration,、clinical center
Topical formulations R & D Center

MaxiNovel upholds the people-oriented company philosophy. It motivates employees to help and support each other; encourages everyone to fully utilize one’s creativity and enthusiasm. The company provides a platform for all the employees to realize the company value and personal value at the same time, to share the company success together.

Culture and Value

April 2017

The 6th China Innovation and Entrepreneurship Competition: 1st place in Guangzhou City, 1st place in Guangdong Province, and Top 8 in China.

April 2018

MaxiNovel clinical product MAX-40279 has been officially granted the orphan drug qualification by the U.S. Food and Drug Administration (FDA).

September 2019

China Shenzhen Innovation and Entrepreneurship Competition: The Second prize in the Biomedical sector

December 2019

Shenzhen Innovation List organized by Shenzhen Broadcasting Group: MaxiNovel JAK inhibitor treatment of autoimmune alopecia was awarded the most promising entrepreneurial project of the year.

December 2019

Nanshan Innovative “Entrepreneurship Star” Competition: 3rd place in the entrepreneurial group of the Biomedical industry competition.

December 2019

MaxiNovel has been awarded a grant by the National New Drug Creation Fund for the clinical study of MAX-40279.